HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Program Description

Advances in HER2-targeted therapies have improved outcomes for patients with HER2-expressing breast cancer. However, HER2-targeted treatment regimens can be complex, and can consist of multiple therapies, with dosing variations, different administration schedules, and unique adverse effects (AEs). This webinar reviews distinctions in HER2 status, including HER2-positive, HER2-low, and HER2-ultralow disease, and the implications of diagnostic testing on treatment selection. The mechanism of action, efficacy, and safety of key HER2-targeted drug classes, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates, as well as novel agents, will be outlined. The discussion will integrate the latest clinical data from trials into treatment sequencing strategies, with a review of recommendations and current organization guidelines for patients receiving frontline, second-line, and subsequent therapy. As these data continue to emerge, oncology pharmacists will maintain their pivotal roles in managing AEs and overcoming access and adherence challenges. This webinar will explore the implications of emerging clinical data for HER2-targeted therapies in practice alongside a discussion of managed care considerations in the integration of new evidence and formulary decisions to reduce barriers to treatment access for patients with HER2+ metastatic breast cancer.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application

Release date: December 5, 2025

Expiration date: December 5, 2026

Learner level: Foundational, Intermediate

Time to complete activity: 1.0 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Illustrate the evolving landscape of HER2-positive (HER2+) metastatic breast cancer (mBC), including current standards of care and emerging sequencing strategies relevant to managed care decision-making 
• Analyze recent clinical trial evidence and evolving HER2-targeted therapies to guide evidence-based formulary development and population health management 
• Explain the implications of new treatment data on access, affordability, and care delivery models to support optimal utilization and equitable outcomes in HER2+ mBC